These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27494368)

  • 1. Use of prasugrel in the setting of clopidogrel hypersensitivity: Case report and systematic review of the literature.
    Siu H; Kaliyadan A; Fischman DL; Nardone E; Poll D; Savage MP
    Platelets; 2016 Dec; 27(8):824-827. PubMed ID: 27494368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prasugrel use in a patient allergic to clopidogrel: effect of a drug shortage on selection of dual antiplatelet therapy.
    Felix-Getzik E; Sylvia LM
    Am J Health Syst Pharm; 2013 Mar; 70(6):511-3. PubMed ID: 23456404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of prasugrel in a patient with clopidogrel hypersensitivity.
    Peppard SR; Held-Godgluck BM; Beddingfield R
    Ann Pharmacother; 2011 Oct; 45(10):e54. PubMed ID: 21896923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
    Kim YS; Lee SR
    Tex Heart Inst J; 2015 Oct; 42(5):483-6. PubMed ID: 26504448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel desensitization: case report and review of published protocols.
    Owen P; Garner J; Hergott L; Page RL
    Pharmacotherapy; 2008 Feb; 28(2):259-70. PubMed ID: 18225971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
    Valenti R; Marcucci R; Comito V; Marrani M; Cantini G; Migliorini A; Parodi G; Gensini GF; Abbate R; Antoniucci D
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1563-70. PubMed ID: 26386764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergic reactions to clopidogrel and cross-reactivity to other agents.
    Lokhandwala J; Best PJ; Henry Y; Berger PB
    Curr Allergy Asthma Rep; 2011 Feb; 11(1):52-7. PubMed ID: 20941557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Same-Day Platelet Inhibition in Patients Receiving Drug-Eluting Stents With or Without Previous Maintenance Thienopyridine Therapy: from the Evaluation of Platelet Inhibition in Patients Having A VerifyNow Assay (EPIPHANY) Trial.
    Lee MS; Shlofmitz E; Haag E; Santiago L; Pollack S; Reichek N; Shlofmitz RA
    Am J Cardiol; 2017 Apr; 119(7):991-995. PubMed ID: 28159194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts.
    Wein B; Coslovsky M; Jabbari R; Galatius S; Pfisterer M; Kaiser C
    Int J Cardiol; 2017 Dec; 248():20-27. PubMed ID: 28823409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
    Migliorini A; Valenti R; Parodi G; Marcucci R; Abbate R; Carrabba N; Gensini GF; Antoniucci D
    Am J Cardiol; 2013 Dec; 112(12):1843-8. PubMed ID: 24063827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).
    Jacob S; Dunn BL; Qureshi ZP; Bandarenko N; Kwaan HC; Pandey DK; McKoy JM; Barnato SE; Winters JL; Cursio JF; Weiss I; Raife TJ; Carey PM; Sarode R; Kiss JE; Danielson C; Ortel TL; Clark WF; Rock G; Matsumoto M; Fujimura Y; Zheng XL; Chen H; Chen F; Armstrong JM; Raisch DW; Bennett CL
    Semin Thromb Hemost; 2012 Nov; 38(8):845-53. PubMed ID: 23111862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of chronic kidney disease on platelet inhibition of clopidogrel and prasugrel in Japanese patients.
    Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Wakabayashi S; Hanaoka H; Kobayashi Y
    J Cardiol; 2017 May; 69(5):752-755. PubMed ID: 27567173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thienopyridines in Acute Coronary Syndrome.
    Goodwin MM; Desilets AR; Willett KC
    Ann Pharmacother; 2011 Feb; 45(2):207-17. PubMed ID: 21304037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Switching from clopidogrel to prasugrel: Efficacy and safety data].
    Yamaç AH; Göktekin O
    Turk Kardiyol Dern Ars; 2015 Oct; 43 Suppl 2():20-4. PubMed ID: 27326447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents.
    Makkar K; Wilensky RL; Julien MB; Herrmann HC; Spinler SA
    Ann Pharmacother; 2006 Jun; 40(6):1204-7. PubMed ID: 16684808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of prasugrel for the secondary prevention of atherothrombosis.
    Spinler SA; Rees C
    J Manag Care Pharm; 2009 Jun; 15(5):383-95. PubMed ID: 19496635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.